Sacubitril (sodium)

Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19[1][2][3].

Product Specifications

CAS Number

[149690-05-1]

Product Name Alternative

AHU-377 (sodium)

UNSPSC

12352005

Hazard Statement

H319, H413

Target

Neprilysin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/sacubitril-sodium.html

Purity

99.95

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(CCC(O[Na])=O)N[C@H](CC1=CC=C(C2=CC=CC=C2)C=C1)C[C@@H](C)C(OCC)=O

Molecular Formula

C24H28NNaO5

Molecular Weight

433.47

Precautions

H319, H413

References & Citations

[1]Hegde, L.G., et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension. BMC Pharmacol 11, P33 (2011) . |[2]Vitiello A, et al. Sacubitril, valsartan and SARS-CoV-2. BMJ Evid Based Med. 2020 Jul 27:bmjebm-2020-111497. |[3]Chrysant SG. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. J Am Soc Hypertens. 2017 Jul;11 (7) :461-468.